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Abstract
Aceruloplasminemia is an autosomal recessive disorder caused by mutations in the ceruloplasmin (CP) gene, and is characterized by a
unique combination of neurovisceral iron overload and iron deficiency anemia. We generated CP-deficient (CP /) mice to investigate the
functional involvement of CP in iron metabolism. The mice showed a marked iron overload in the liver and mild iron deficiency anemia. We
examined the expression of iron-metabolism genes in the duodenum and liver using TaqMan RT-PCR. The divalent metal transporter 1
(DMT1), ferroportin 1 (FPN1), and hephaestin (HEPH) genes were not up-regulated in the duodenum from CP / mice. These data suggest
that the mechanism of hepatic iron overload in aceruloplasminemia is quite different from that in hemochromatoses and atransferrinemia. In
the liver, CP / mice showed no increase of gene expression for DMT1 and transferrin receptors (TFR and TFR2), indicating that none of
the known pathways of iron uptake is activated in hepatocytes of CP / mice. This result supports the hypothesis that CP mainly acts to
release iron from cells in the liver.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Aceruloplasminemia is an iron-overloading disorder
caused by mutations in the ceruloplasmin (CP) gene, and
is clinically characterized by diabetes mellitus, retinal
degeneration, mild iron deficiency anemia, and neurological
symptoms [1–4]. Laboratory findings include deficient
serum CP, decreased serum iron, normal or decreased trans-
ferrin saturation rate, and increased serum ferritin. Marked
hemosiderosis is seen in the liver, pancreas, and brain in
affected individuals [4]. These findings strongly support that
CP is involved in iron metabolism through its ferroxidase
activity. However, the precise role of CP in iron homeostasis
and mechanism of iron overload in aceruloplasminemia
have remained unclear.
Iron is an element essential for a wide spectrum of
biologic functions, whereas excess iron is toxic because of
its insolubility at physiologic pH and its ability to generate
reactive oxygen species. Iron homeostasis is maintained by
the strict regulation of iron absorption from the intestine,
rather than iron excretion [5]. Recently, several important
molecules involved in iron transport have been identified by
molecular genetic analyses of patients and animals with
abnormal iron metabolism. They include hereditary hemo-
chromatosis protein (HFE) [6], transferrin receptors (TFR [7]
and TRF2 [8,9]), divalent metal transporter 1 [10,11]
(DMT1, previously named NRAMP2 and DCT1), ferropor-
tin 1 [12] (FPN1, also called IREG1 [13] or MTP1 [14]), and
a CP homologue, hephaestin (HEPH) [15]. DMT1, FPN1,
and HEPH are highly expressed in the intestine (mainly in
the duodenum) and are considered to be a brush border
transporter of ferrous iron, a basolateral iron exporter, and a
basolateral multi-copper ferroxidase, respectively. The iden-
tification of these iron-metabolism proteins has contributed
to enlarging our knowledge of iron homeostasis.
To elucidate iron kinetics in a CP-deficient state, we
generated genetically CP-deficient (CP /) mice. The mice
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were clinically well up to at least the age of 60 weeks, but
showed a significant increase in iron storage in the liver not
later than age 20 weeks. We examined the expression of
iron-metabolism genes, DMT1, FPN1, HEPH, TFR, and
TFR2, in the duodenum and liver of CP /  mice to
investigate iron kinetics in a CP-deficient state and to
deduce functional involvement of CP in iron absorption
and transport. We discuss the iron-overloading mechanism
in aceruloplasminemia compared with other hereditary iron-
overloading disorders.
2. Materials and methods
2.1. Generation of CP/ mice
We generated a CP null allele by deletion of essential
sequence from exon 1, as follows. A 6.5-kb mouse genomic
DNA fragment containing exon 1 of the CP gene was
isolated from a 129/SvJ mouse genomic library (Stratagene)
and subcloned into Bluescript II SK+ vector (Stratagene). A
pMC1neo polyA cassette (Stratagene) was then inserted
between two Bpu1102I sites ( + 16 and  650, + 1 denotes
the translation start site) in the reverse orientation, followed
by the insertion of the 1.8-kb herpes simplex virus thymi-
dine kinase gene into the 3V-end of the genomic fragment
(Fig. 1A). It was linearized by cleavage at the unique NotI
site, before transfection by electroporation into E14 embry-
onic stem (ES) cells obtained from the inbred mouse strain
129/SvJ. Positive clones were selected by challenging the
cultured ES cells with G418 (300 Ag/ml) and ganciclovir (2
AM). Surviving colonies were then screened for the
expected homologous recombination by PCR using LA
Taq polymerase (TaKaRa) and primers; primer 1 (CP intron
sequence outside the targeting vector): 5V-TAA GAT GCT
GGA GAA GCC ACA GGA GAC TGT AG-3V, and primer
Fig. 1. Generation of CP / mice. (A) A schematic diagram of the CP gene (top), the CP-mutant targeting vector (middle), and the predicted structure of the
CP null allele after homologous recombination (bottom). The restriction sites of Bpu1102I, HindIII, and NotI are shown. The HindIII-restriction sites
(rectangles) generate the 4.0- and 4.4-kb restriction fragments diagnostic for wild-type and properly targeted alleles, respectively, as shown in (C). The Neo
(neomycin resistance) and HSV TK (herpes simplex virus thymidine kinase) genes refer to the positive and negative selective markers, respectively. PCR
primers and 3Vexternal probe are indicated. (B) PCR analysis for identification of the mouse genotype. The PCR product generated with primers 1 and 3
indicates the wild-type allele and that with primers 1 and 2 indicates the targeted allele. (C) Southern analysis of HindIII digest of genomic DNA isolated from
mouse tail cuts. The bands of 4.4 and of 4.0 kb indicate mutant and wild-type CP alleles, respectively. (D) Immunoblot analysis of mouse serum with
polyclonal anti-human CP antibody. CP protein is completely absent in serum from CP / mice.
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2 (neo cassette sequence): 5V-CTG CGT GTT CGA ATT
CGC CAA TGA CAA GAC GCT GG-3V. The PCR results
were confirmed by Southern blot analysis of EcoRI- or
HindIII-digested genomic DNA using the external probe
(Fig. 1A). Probing with the neo gene confirmed the presence
of a single mutant allele. Targeted ES cells containing one
disrupted CP allele were injected into C57BL/6 blastocysts
as described previously [16] and chimeric mice were
derived from two independent clones. Heterozygous F1
offspring from the ES clones were independently inter-
crossed to generate F2 homozygous mice on the BALB/c
strain background. To identify the genotype of the offspring,
genomic DNA from the tails was amplified by PCR using
oligonucleotide primers; primers 1 and 3 (sequence from
exon 1): 5V-GCA ACA TTA AAT TGT GTC AGC CAA
GC-3Vfor wild-type allele amplification and primers 1 and 2
for targeted allele amplification (Fig. 1B). Southern blot
analysis of HindIII-digested genomic DNA with the 3V
external probe that yielded a 4.0-kb band in the wild-type
allele and a 4.4-kb band in the targeted allele was also
performed to confirm the PCR results (Fig. 1C).
Mice fed ad libitum on a normal chow diet (containing
122 Ag/g of iron and 77.2 Ag/g of copper) were kept on a
12:12 light/dark cycle. Body weight was recorded once
every 4 weeks.
2.2. Immunoblot analysis and measurement of serum
ferroxidase activity
Liver tissue was homogenized and boiled for 6 min in a
buffer containing 10% SDS, 70 mM Tris–HCl (pH 6.7), 10
mM EDTA, and 5% h-mercaptoethanol. Serum was added
to an equal volume of buffer containing 4% SDS, 100 mM
Tris–HCl (pH 6.7), and 10% h-mercaptoethanol, and boiled
for 6 min. The liver or serum protein at 20 Ag/lane was then
separated on a 7.5% SDS-polyacrylamide gel and electro-
transferred onto a polyvinylidene difluoride membrane
(Millipore). The blot was then incubated with a rabbit
polyclonal anti-human CP antibody (DAKO, A0031) at a
1:500 dilution. We had previously confirmed that this anti-
body could clearly detect both the secreted form and the
glycosylphosphatidylinositol-anchored form [17] of mouse
CP. Immune complexes on the blot were detected with a
1:3000 dilution of horseradish peroxidase-conjugated goat
anti-rabbit IgG (BIO-RAD) and ECL Western blotting
detection reagents (Amersham Pharmacia Biotech). Serum
ferroxidase activity was measured using Fe2 + ions as the
substrate, as described previously [18].
2.3. Histopathology
Under anesthesia with diethylether, organs were removed
from 20-, 40- and 60-week-old CP / mice and CP+/ +
littermates used as controls. Tissues were fixed in 10%
formalin, embedded in paraffin, sectioned, and mounted on
slides for staining with hematoxylin and eosin. Other sets of
slides were stained with potassium ferrocyanide (Berlin
blue) to detect ferric iron in tissues, and counterstained with
nuclear fast red.
2.4. Measurement of metal content
CP / mice and CP+/ + littermates were anesthetized
with diethylether and systemically perfused with saline from
the left ventricle after thoracotomy to remove whole blood
from organs. Iron and copper contents of tissues were
analyzed as described previously [19]. Briefly, the tissues
were collected into pre-weighed glass tube, reweighed to
calculate the weight of wet specimen, then lyophilized and
weighed again to calculate the weight of dried specimen.
After sixfold wet tissue weight of nitric acid was added, the
specimens were heated at 80 jC for 1 to 2 days, and
dissolved with 2 ml of 50 mM hydrochloric acid under
ultrasonic agitation at 50 jC. The supernatant of the
centrifuged samples was analyzed by atomic absorption
spectrophotometer after appropriate dilution with water.
The iron and copper contents (Ag/g of dry tissue) were
calculated from the results of this analysis and the dilution
factor. Hematological parameters and serum iron content
were measured on other series of mice.
2.5. Quantitative TaqMan RT-PCR
Total RNAwas isolated from tissues of 20- and 40-week-
old CP / male mice and CP+/ + male littermates using TRI
Reagent (Sigma), and treated with RNase-free DNase (Stra-
tagene). The RT reaction was performed with 1 Ag of
DNase-treated total RNA, random hexamers, and MMLV
reverse transcriptase (Applied Biosystems) according to the
manufacturer’s instructions. TaqMan PCR primers and Taq-
Man probes used for quantification of DMT1, FPN1,
HEPH, TFR, and TFR2 cDNAs were designed using Primer
Express Software (Applied Biosystems) (Table 1). The
primers and probe for DMT1 detected a total of two splice
variants of DMT1 mRNA, namely, the IRE (iron responsive
element) form and the non-IRE form. These probes consist
of an oligonucleotide with a 5V-reporter fluorescent dye (6-
carboxyfluorescein) and a 3V-quencher dye (6-carboxy-tet-
ramethyl-rhodamine). Each cDNA was amplified by PCR
using each primer set and duodenum cDNA as the template
for DMT1, FPN1, HEPH, and TFR, or liver cDNA for
TFR2. The products were inserted into the pCR II vector
(Invitrogen) and cloned. The serially diluted plasmids con-
taining each cDNA were used as the standards for amplifi-
cation. PCR reaction mixture was prepared according to the
manufacturer’s instructions and the amplification was car-
ried out in MicroAmp optical 96-well reaction plates
(Applied Biosystems) in the ABI Prism 7700 Sequence
Detection System (Applied Biosystems). Each reaction
was performed in triplicate. The cDNA quantities were
normalized to the amount of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA, which was quantified
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using Rodent GAPDH Control Reagents (VIC probe,
Applied Biosystems).
2.6. Statistical analysis
Data were expressed as meansF standard deviations. We
used the unpaired Student’s t test to evaluate the differences
in hematological parameters, serum and tissue metal content,
serum ferroxidase activity, and gene expression level on
quantitative TaqMan RT-PCR between CP+/ + and CP /
mice.
3. Results
3.1. Clinical phenotype of CP/ mice
Immunoblot analysis of serum and liver showed that
neither the 132-kDa full-length nor smaller sized truncated
CP protein was detected in CP / mice (Fig. 1D), confirm-
ing that targeted disruption of the CP gene was completely
attained. Serum ferroxidase activity was reduced in CP+/
mice [302.0F 85.6vs. 523.5F 139.4U/l (P= 0.002);CP+/:
N = 5, CP+/ +: N = 11] and negligible in CP /  mice
[53.7F 31.1 vs. 523.5F 139.4 U/l ( P = 3.7 10 7);
CP /: N = 16, CP+/ +: N = 11].
CP+/ and CP /mice appeared normal at birth. Of 228
offspring genotyped, 58 (25.4%) were wild-type (CP+/ +),
115 (50.4%) heterozygous for the CP null allele (CP+/),
and 55 (24.1%) homozygous (CP /). CP / mice deve-
loped and grew normally. They survived into their 60–
80th weeks after birth. CP / mice did have mild micro-
cytic anemia [12.6F 1.0 vs. 15.9F 0.3 g/dl (P= 0.0043),
48.5F 4.0 vs. 55.8F 1.9 fl (P= 0.028), and 28.5F 0.6 vs.
29.2F 0.4 g/dl (P= 0.097) of hemoglobin content, mean
corpuscular volume, and mean corpuscular hemoglobin
concentration, respectively; 20-week-old mice; CP / :
N = 4, CP+/ +: N = 5] and lower serum iron content (Table 2).
3.2. Hepatic iron overload in CP/ mice
Hematoxylin and eosin staining of the brain, duodenum,
heart, kidney, liver, lung, pancreas, and retina of 20-, 40-,
and 60-week-old CP / mice derived from two independ-
ent clones revealed no structural abnormalities (data not
shown). Iron staining (Berlin blue staining) of the liver from
CP / mice showed increased iron deposition (Fig. 2B),
while little iron deposition was seen in the liver of CP+/ +
mice (Fig. 2A). Iron deposition was observed in the cyto-
plasm of both hepatocytes and Kupffer cells, not only at the
periportal areas but also around the central veins (Fig. 2C).
Iron staining of the brain, duodenum (Fig. 2D), heart,
kidney, lung, pancreas, and retina showed no evidence of
abnormal iron deposition up to at least the age of 60 weeks.
Although there was no significant difference in iron
content between CP+/ + and CP / mice in the cerebrum
and duodenum, hepatic iron content of CP / mice was
significantly (f 3.4-fold) higher than that of CP+/ + mice at
both 20 and 40 weeks of age (Table 2). We also evaluated
copper content of these organs, but no significant differ-
ences were found between CP+/ + and CP / mice (data not
shown).
3.3. Expression of iron-metabolism genes
The expression of iron-metabolism genes was measured
by means of quantitative TaqMan RT-PCR. DMT1, FPN1,
andHEPHmRNAwere evaluated in the duodenum, which is
the major site of iron absorption, and DMT1, FPN1, HEPH,
Table 2
Serum and tissue iron content in CP+/ + and CP / mice
Age Genotype Serum iron [Ag/dl] Tissue iron [Ag/g of dry tissue]
Cerebrum Duodenum Liver
20 w CP+/ + 194.7F 18.0 (3) 70.6F 13.0 (7) 219.9F 124.2 (7) 419.1F169.0 (7)
CP /  102.0F 32.5** (6) 73.3F 11.2 (7) 221.9F 123.7 (7) 1425.7F 557.2** (7)
40 w CP+/ + 205.8F 31.8 (5) 72.0F 7.1 (6) 188.4F 19.3 (5) 539.0F 99.1 (6)
CP /  90F 58.3** (6) 76.2F 7.3 (5) 169.3F 30.7 (4) 1822.0F 903.1* (5)
The numbers of examined mice are shown in parenthesis. *P< 0.05, **P < 0.01 compared with the corresponding data of CP+/ + mice.
Table 1
Sequence of TaqMan RT-PCR primers and probe used for quantification of
gene expression
DMT1 primers 5V-AAC CAA CAA GCA GGT GGT TGA-3V
5V-CTT TGT AGA TGT CCA CAG CCA
GAG T-3V
probe 5V-CCA TGC TGA CCT CTT TCC CAG TGA
CAA C-3V
FPN1 primers 5V-AAG GAT TGA CCA GCT AAC CAA CA-3V
5V-CAG CCA ATG ACT GGA GAA CCA-3V
probe 5V-CCA TGG CTG TCG GCC AGA TTA TGA
CAT-3V
HEPH primers 5V-GCC TGG GCA CAG AGA CTG AT-3V
5V-AAG GTG TGA GGA AAG AGC ATG AC-3V
probe 5V-TTC GAG GGC AAC ACT GTG CAG
CTT C-3V
TFR primers 5V-CAG AAA GTT CCT CAG CTC AAC CA-3V
5V-GTT CAA TTC AAC GTC ATG GGT AAG-3V
probe 5V-AGC CAC TTC CGC TGC TGT ACG
AAC C-3V
TFR2 primers 5V-AGC TGG GAC GGA GGT GAC TT-3V
5V-TCC AGG CTC ACG TAC ACA ACA-3V
probe 5V-AGG GCT ACC TCA GCG TGC TAC ACC
TCA-3V
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Fig. 2. Berlin blue iron stain counterstained with nuclear fast red of organs from 40-week-old mice. Liver sections of CP+/ + (A) and CP / mice (B, C) and
duodenum section of CP / mice (D) are shown. In the CP /  mouse, markedly increased iron deposition is seen in the liver, where the cytoarchitecture is
well preserved (B). Iron deposition was observed in the cytoplasm of both hepatocytes and Kupffer cells, not only at the periportal areas but also around the
central veins (CV) (C). In the CP / mouse, neither structural abnormality nor abnormal iron deposition is seen in the duodenum (D).
Fig. 3. Quantification of iron-metabolism gene expression by TaqMan RT-PCR. DMT1, FPN1, and HEPH mRNAwere evaluated in duodenum (A) and DMT1,
FPN1, HEPH, TFR, and TFR2 mRNAwere quantified in liver (B). Total RNA extracted from tissues of 20- and 40-week-old CP+/ + and CP / male mice was
used for reverse transcription and PCR amplification. The amount of each gene transcript relative to the GAPDH transcript is shown as meanF standard
deviations. *P < 0.05; **P < 0.01; ***P< 0.001. Because HEPH gene expression was very low in the liver from both CP+/ + and CP /  mice, those results are
not shown.
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TFR, and TFR2 mRNA in the liver. In the duodenum (Fig.
3A), there was no difference in the expression of the DMT1,
FPN1, and HEPH genes between CP+/ + and CP / mice at
20 weeks of age. Although the expression of these three
genes had a tendency to increase with age in CP+/ + mice,
expression of the DMT1 and FPN1 genes tended to decrease
and the HEPH gene showed a reduced rate of increase in
CP / mice. There was a significant difference in the level
of expression of the FPN1 gene between CP+/ + and CP /
mice at 40 weeks of age (P= 0.0004).
In the liver (Fig. 3B), expression of the DMT1 gene in
CP / mice was reduced in comparison with CP+/ + mice at
40 weeks of age (P= 0.0085). The levels of FPN1 gene
expression in the liver revealed no difference between CP+/+
and CP / mice. CP deficiency significantly lowered TFR
gene expression in the liver at both 20 (P= 0.044) and 40
(P= 0.0004) weeks of age. TaqMan RT-PCR showed a
tendency towards lower TFR2 gene expression in the liver
from CP /  than CP+/ + mice, but this did not reach
significance (P= 0.142, 0.059 at 20 and 40 weeks of age,
respectively). The expression levels of the HEPH gene were
very low in the liver of both CP+/ + and CP / mice at the
age of either 20 or 40 weeks (data not shown).
4. Discussion
In the present study, we have generated CP / mice
and investigated tissue iron storage and expression of
iron-metabolism genes in the duodenum and liver. These
CP / mice showed an iron overload in the liver in
combination with hypoferremia and mild microcytic anemia,
suggesting that abnormal iron kinetics in patients with
aceruloplasminemia is faithfully modeled here. On the other
hand, we found no evidence of abnormal iron overload in
other organs including brain and pancreas up to the age of 60
weeks, where marked iron overload is observed in affected
individuals [4]. Short life span and poor cerebral vasculari-
zation may be the reasons for absence of iron overload in the
brain of CP / mice. Harris et al. [20] generated CP /
mice independently, and found increased iron content in the
liver and spleen, but not either hypoferremia or anemia in
their CP / mice. The difference in hematological behavior
is likely to have arisen due to targeting different strains of the
mice; we generated CP /  mice in the BALB/c strain
background, whereas they used black Swiss–Webster mice
[20].
Investigating the expression of the genes involved in iron
transport in iron-depleting or iron-overloading conditions,
although it is not a direct analysis of iron transport, may
provide insights important for a better understanding of iron
metabolism. Several studies have demonstrated that duode-
nal DMT1 and FPN1 expression is increased in patients with
HFE-associated [13,21,22] or non-HFE-associated [21]
hemochromatosis, HFE-deficient mice [23,24], hypotrans-
ferrinemic (homozygous hpx) mice [13,25], and iron-defi-
cient states [11,13,14,26,27]. By contrast, up-regulation of
the DMT1 and FPN1 genes was not found in the duodenum
of CP / mice. This supports a previous ferrokinetic study
by Harris et al. [20], which showed no difference in the rate
of intestinal iron absorption between their CP / mice and
control mice. The profile of duodenal DMT1 expression in
CP / mice is consistent with the manner of regulation
through IRE/IRP (iron regulatory protein) system [28] since
DMT1 transcripts have IREs in the 3V-untranslated region
(3V-UTR) and CP deficiency does not affect iron content in
enterocytes. FPN1 transcripts contain IRE in the 5V-UTR,
but the modes of regulation other than those involving the
IRE/IRP system have been speculated for duodenal FPN1
expression [13,14]. Reduction of duodenal FPN1 expression
at the age of 40 weeks in CP / mice may be explained by
that the iron store regulator acts more strongly than the
erythropoietic regulator, although these regulators have not
been clearly identified [5]. The profile of duodenal DMT1
and FPN1 expression in CP / mice suggests that the
mechanism responsible for hepatic iron overload in acer-
uloplasminemia is quite different from that in hereditary
hemochromatoses and atransferrinemia.
What mechanism functions in the process of tissue iron
overload in CP-deficient state is open to discussion. To date,
controversial results have accumulated on the role for CP in
iron transport via its ferroxidase activity. Classical studies
suggested that CP promotes iron efflux from the storage
cells to plasma in vivo [29,30]. Some in vitro experiments
were in favor of this possibility [31,32]. In addition, studies
on human aceruloplasminemia and CP / mice strongly
suggested an iron-releasing function of CP [1,20]. On the
other hand, Fox et al. [33,34] and Qian et al. [35] demon-
strated that CP has a role in iron uptake rather iron release.
The different results might be partly due to experimental
conditions, therefore, we are still awaiting a final answer on
the role for CP in iron metabolism. The expression profile
of iron-metabolism genes in the iron-overloaded liver of
CP / mice may provide a clue to solve this intriguing
issue. Hepatocytes have a transport system to take up both
transferrin (TF)-bound and non-TF-bound iron [36]. TFR
and TFR2 take TF-bound iron in hepatocytes, and DMT1 is
involved in both TF-bound and non-TF-bound iron uptake
[27,36]. In our study, hepatic DMT1, TFR, and TFR2
expression in CP / mice was down-regulated in the face
of enlarged iron store. The significant suppression of DMT1
and TFR expression is in reasonable agreement with the
regulation via IRE/IRP system because DMT1 and TFR
transcripts, but not TFR2 transcripts [37], have IREs in 3V-
UTR and are regulated directly by tissue iron status. More
importantly, these results indicate that no known pathway of
iron uptake is activated in hepatocytes in CP / mice.
Thus, it is likely that CP mainly acts to release iron from
hepatocytes and that its deficiency directly causes iron
overload, although continued TFR2-mediated iron uptake
may also contribute to hepatic iron accumulation. If this is
not the case, we should presume that unknown CP-inde-
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pendent pathways of iron uptake will be activated in
hepatocytes in a CP-deficient state.
Lastly, we should discuss on duodenal HEPH expression
briefly. FPN1 requires an auxiliary ferroxidase activity to
mediate iron release across the basolateral membrane of
enterocytes. In a classical schema, CP was considered as a
major ferroxidase in this compartment [38]. Harris et al. [20]
showed that the rate of intestinal iron absorption was not
affected in CP /  mice. On the other hand, sex-linked
anemia (sla) mice, which bear a mutation of the HEPH gene,
have a block in intestinal iron transport and showmoderate to
severe microcytic hypochromic anemia [15]. Furthermore,
we found no increase in duodenal HEPH expression in
CP / mice. Taken together, it is concluded that CP is less
critical than HEPH for intestinal iron absorption.
We have attempted to understand the iron-overloading
mechanism in a CP-deficient state by evaluating the expres-
sion of iron-metabolism genes. Based on our data, acerulo-
plasminemia is characterized by a specific iron-overloading
mechanism different from other disorders such as hereditary
hemochromatosis and atransferrinemia. Further examination
using each animal model may promote a better understand-
ing of the pathogenesis peculiar to each iron metabolism
disorder and may facilitate development of therapeutic
approaches appropriate for each pathological condition.
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